Proof-of-concept study of Bepranemab in patients with Alzheimer's Disease
Latest Information Update: 04 Aug 2020
At a glance
- Drugs Bepranemab (Primary)
- Indications Alzheimer's disease
- Focus Proof of concept; Therapeutic Use
- 04 Aug 2020 New trial record
- 28 Jul 2020 According to an UCB media release, the company will fund and perform a proof-of-concept study in AD and, upon availability of the results of that study, Genentech has the right to progress with the development or return full rights back to UCB.